Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161807 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
A NA study, sponsored by Theranica.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT04161807 is a NA study that has completed, run by Theranica. The registered enrollment target is 42 participants.
The verdict
NCT04161807, a NA study, has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The study duration consists of a 4 weeks of active treatment with the device in about 40 patients.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2020-02-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04161807
The ClinicalTrials.gov registry entry for NCT04161807 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT04161807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04161807 about?
NCT04161807 is a clinical study titled "Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine". This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with chronic migraine. The device delivers transcutaneous electrical stimulation ...
What is the current status of trial NCT04161807?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2019-09-18. Estimated completion is 2020-02-18.
What interventions are being tested in trial NCT04161807?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT04161807?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.